Pluri Inc. (PLUR)

Pluri Inc. (PLUR) Healthcare & Pipeline Overview

Pluri Inc. is an Israeli biotechnology firm specializing in placenta-based cell therapy, advancing product candidates like PLX-PAD for muscle recovery and acute respiratory distress syndrome, and PLX-R18 for hematologic conditions. The company leverages its proprietary platform to address significant unmet medical needs in inflammatory and regenerative medicine, operating within the highly regulated healthcare sector.

What Is the Investment Thesis for PLUR?

Pluri Inc. presents an investment profile centered on its advanced clinical-stage biotechnology pipeline, particularly its placenta-based cell therapy candidates. The company's primary value driver is the progression of PLX-PAD, currently in Phase III clinical trials for muscle recovery after hip fracture surgery. Successful completion of this late-stage trial and subsequent regulatory approval would represent a significant commercialization catalyst, addressing a substantial market need. Additionally, PLX-PAD is being evaluated in Phase II for acute respiratory distress syndrome (ARDS) and Phase I/II for steroid-refractory graft versus host disease (GvHD), offering multiple potential indications. The development of PLX-R18 for hematopoietic recovery and acute radiation syndrome further diversifies the pipeline, targeting critical, often niche, medical challenges. Financially, Pluri Inc. operates with a market capitalization of $21.49M and a gross margin of 19.0%. However, its profit margin of -2424.7% reflects the substantial research and development expenditures typical of a clinical-stage biotech company prior to commercialization. Key risks include the inherent uncertainties of clinical trials, potential regulatory hurdles, and the ongoing need for capital to fund its extensive development programs. The company's Beta of 0.75 suggests a relatively lower volatility compared to the broader market, which is notable given its sector. The thesis hinges on the successful advancement and eventual commercialization of its proprietary cell therapies, transforming its R&D investments into revenue-generating assets.

Based on FMP financials and quantitative analysis

PLUR Key Highlights

• Market Capitalization: $0.03 billion, indicating a small-cap biotechnology firm focused on early-stage development.
• Gross Margin: 19.0%, reflecting the early-stage nature of a company primarily focused on R&D rather than commercial sales.
• Profit Margin: -2424.7%, underscoring significant ongoing investment in research and development without substantial revenue generation.
• Beta: 0.75, suggesting lower volatility compared to the broader market, which is notable for a biotechnology company.
• Clinical Pipeline: PLX-PAD is in Phase III for muscle recovery after hip fracture surgery, representing a key late-stage asset.

Who Are PLUR's Competitors?

PLUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PLUR's Key Strengths?

• Proprietary placenta-based cell therapy platform with unique biological properties.
• Advanced clinical pipeline, including PLX-PAD in Phase III for muscle recovery after hip fracture surgery.
• Diverse pipeline targeting multiple indications across inflammatory, muscle injury, and hematologic conditions.
• Experienced team managing complex biotechnology R&D and clinical trials.

What Are PLUR's Weaknesses?

• Significant negative profit margin (-2424.7%) due to high R&D expenditures.
• Small market capitalization ($0.03B) indicating limited financial scale.
• Dependence on successful clinical trial outcomes for future commercial viability.
• High capital requirements to fund ongoing research, development, and regulatory processes.

What Could Drive PLUR Stock Higher?

• Announcement of results from the Phase III clinical trial for PLX-PAD in muscle recovery after hip fracture surgery, expected to be a significant data readout.
• Further clinical trial advancements or initiation of new trials for PLX-PAD in acute respiratory distress syndrome (ARDS) or steroid-refractory graft versus host disease (GvHD).
• Progress in the development and clinical evaluation of PLX-R18 for incomplete hematopoietic recovery or acute radiation syndrome, potentially leading to key milestones.
• Continued research and development efforts to expand the company's proprietary placenta-based cell therapy pipeline and explore new indications.
• Potential formation of strategic partnerships or licensing agreements with larger pharmaceutical companies to support further development and commercialization.

What Are the Key Risks for PLUR?

• Financial-distress signal — its Altman Z-Score of -28.79 sits in the distress zone (elevated bankruptcy risk).
• High research and development expenses contributing to a significant negative profit margin (-2424.7%), necessitating continuous capital raises.
• Clinical trial failures or unexpected delays for lead product candidates like PLX-PAD and PLX-R18, impacting timelines and market potential.
• Stringent and evolving regulatory hurdles and lengthy approval processes inherent to advanced cell therapies, which could delay market entry.
• Intense competition within the biotechnology and regenerative medicine sectors, potentially limiting market share or pricing power upon commercialization.
• Dependence on external funding and investor confidence to sustain operations and extensive clinical development programs through to commercialization.

What Are the Growth Opportunities for PLUR?

• PLX-PAD for Muscle Recovery after Hip Fracture Surgery: The ongoing Phase III clinical trial for PLX-PAD in muscle recovery post-hip fracture surgery represents a significant growth driver. Hip fractures are a major public health concern, particularly among the elderly, often leading to long-term disability and reduced mobility. The global market for orthopedic rehabilitation and regenerative therapies for musculoskeletal injuries is substantial, driven by an aging population and increasing incidence of fractures. Successful trial completion and regulatory approval could position PLX-PAD as a novel therapeutic option, potentially reducing recovery times and improving patient outcomes, thereby capturing a significant share in this established medical segment.
• PLX-PAD for Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19: The Phase II clinical trial for PLX-PAD in treating ARDS associated with COVID-19 offers another substantial growth opportunity. ARDS is a severe lung condition with high mortality rates, and while the immediate COVID-19 pandemic may subside, ARDS remains a critical challenge in various clinical contexts, including sepsis and trauma. The market for ARDS treatments, particularly those that can modulate inflammation and promote tissue repair, is considerable. If PLX-PAD demonstrates efficacy in improving lung function and reducing inflammation, it could address a persistent unmet medical need in critical care, extending its market reach beyond the initial COVID-19 indication.
• PLX-PAD for Steroid-Refractory Graft Versus Host Disease (GvHD): The Phase I/II clinical trial for PLX-PAD in steroid-refractory GvHD targets a severe and often life-threatening complication of allogeneic hematopoietic stem cell transplantation. Patients who do not respond to standard steroid treatments have limited options and poor prognoses. The market for GvHD therapies, particularly for refractory cases, is a high-value niche due to the severity of the condition and the specialized patient population. Demonstrating safety and efficacy in this indication could establish PLX-PAD as a crucial therapeutic intervention, providing a much-needed treatment for a vulnerable patient group and securing a strong position in the orphan drug market.
• PLX-R18 for Incomplete Hematopoietic Recovery: The development of PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation addresses a critical post-transplant complication. Patients undergoing these procedures often experience prolonged periods of low blood cell counts, increasing their risk of infection and other complications. The market for supportive care and regenerative therapies in oncology and transplantation is robust. PLX-R18, by potentially accelerating and improving hematopoietic recovery, could significantly enhance patient safety and reduce hospital stays, offering a valuable addition to post-transplant care protocols and improving outcomes for a specialized patient population undergoing life-saving treatments.
• PLX-R18 for Acute Radiation Syndrome (ARS): PLX-R18's potential as a solution for acute radiation syndrome (ARS) represents a unique and strategically important growth opportunity. ARS is a severe condition resulting from high-dose radiation exposure, with limited effective treatments. While a niche market driven by emergency preparedness and biodefense, the need for such a therapy is critical for national security and public health. Government agencies and military organizations are key potential customers for ARS countermeasures. Successful development and potential stockpiling agreements could provide a stable, high-value revenue stream, positioning Pluri Inc. as a leader in a specialized, high-impact medical countermeasure field.

What Opportunities Does PLUR Have?

• Large unmet medical needs in targeted therapeutic areas, offering substantial market potential.
• Potential for multiple indications for lead product candidates, expanding market reach.
• Strategic partnerships or licensing agreements with larger pharmaceutical companies to accelerate development and commercialization.
• Advancements in regenerative medicine and cell therapy creating a more receptive market and regulatory environment.

What Threats Does PLUR Face?

• Risk of clinical trial failures or delays, which could significantly impact product development and company valuation.
• Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative therapies.
• Stringent and evolving regulatory hurdles for cell therapy products, leading to lengthy and costly approval processes.
• Challenges in securing adequate funding to sustain extensive R&D and clinical programs.

What Are PLUR's Competitive Advantages?

• Proprietary placenta-based cell therapy platform and associated intellectual property.
• Extensive clinical trial data and regulatory progress for lead candidates like PLX-PAD.
• Specialized manufacturing processes and expertise required for large-scale cell therapy production.
• Potential for first-in-class or best-in-class therapies addressing specific unmet medical needs.

What Does PLUR Do?

Pluri Inc., headquartered in Haifa, Israel, is a pioneering biotechnology company established in 2001, initially operating as Pluristem Therapeutics Inc. The company underwent a name change to Pluri Inc. in July 2022, signifying its evolving strategic focus within the regenerative medicine landscape. With a dedicated team of 106 employees, Pluri Inc. is at the forefront of developing innovative placenta-based cell therapy product candidates. These therapies are specifically engineered to address a broad spectrum of critical medical conditions, including various inflammatory disorders, severe muscle injuries, and complex hematologic conditions, representing areas of significant unmet medical need. At the core of Pluri Inc.'s pipeline are its proprietary placental expanded (PLX) based cell therapy products. The most advanced candidate, PLX-PAD, is currently undergoing rigorous clinical evaluation across multiple indications. It is in Phase III clinical trials for muscle recovery following surgery for hip fracture, a condition that impacts a large elderly population and often leads to prolonged rehabilitation and reduced quality of life. Furthermore, PLX-PAD is also being investigated in Phase II clinical trials for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, highlighting its potential in critical care settings. Another crucial application for PLX-PAD is its evaluation in a Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease (GvHD), a severe complication often seen after allogeneic hematopoietic stem cell transplantation. Beyond PLX-PAD, Pluri Inc. is actively developing PLX-R18, another promising cell therapy candidate. PLX-R18 is being developed to address incomplete hematopoietic recovery following hematopoietic cell transplantation, a critical challenge for patients undergoing such intensive treatments. Additionally, PLX-R18 is being explored as a potential solution for the treatment of acute radiation syndrome, a severe and life-threatening condition that could arise from radiological emergencies. Pluri Inc.'s commitment to leveraging the unique biological properties of placental cells positions it as a key player in the advanced cell therapy space, aiming to provide novel therapeutic options for complex diseases. The company's strategic focus on clinical development underscores its long-term vision to bring these innovative therapies to market.

What Products and Services Does PLUR Offer?

• Develops proprietary placenta-based cell therapy product candidates.
• Focuses on treating multiple inflammatory conditions using advanced cell therapies.
• Targets muscle injuries, including recovery after hip fracture surgery, with its PLX-PAD product.
• Addresses hematologic conditions, such as incomplete hematopoietic recovery, with PLX-R18.
• Advances PLX-PAD through various clinical trial stages, including Phase III for muscle recovery and Phase II for ARDS.
• Conducts research and development for PLX-R18 as a potential treatment for acute radiation syndrome.
• Operates as a biotechnology company headquartered in Haifa, Israel.
• Aims to bring innovative regenerative medicine solutions to market for unmet medical needs.

How Does PLUR Make Money?

• Primarily an R&D-focused biotechnology company, aiming for regulatory approval of its cell therapy products.
• Future revenue generation is anticipated from the commercialization of approved therapies, following successful clinical trials.
• Potential for licensing agreements, strategic collaborations, or partnerships with larger pharmaceutical entities for product development and distribution.
• Currently relies on capital raises and investments to fund extensive clinical development, research, and operational expenses.

What Industry Does PLUR Operate In?

Pluri Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically focusing on the advanced therapeutic area of cell therapy and regenerative medicine. This sector is characterized by intense research and development, high regulatory barriers, and the potential for transformative medical breakthroughs. Global trends indicate a growing demand for innovative treatments for chronic diseases, age-related conditions, and conditions with limited existing therapeutic options, aligning directly with Pluri Inc.'s focus on inflammatory, muscle injury, and hematologic conditions. The competitive landscape includes numerous established pharmaceutical companies and emerging biotech firms developing various cell and gene therapies. Pluri Inc. differentiates itself through its proprietary placenta-based cell expansion technology, which offers unique biological properties and potential manufacturing advantages. The company's positioning with late-stage clinical assets like PLX-PAD places it among a subset of biotech firms nearing potential commercialization, although significant hurdles remain in a market driven by clinical efficacy and safety data.

Who Are PLUR's Key Customers?

• Ultimately, patients suffering from inflammatory, muscle injury, and hematologic conditions that Pluri Inc.'s therapies aim to treat.
• Healthcare providers, including hospitals, clinics, and specialized medical centers, that would administer approved cell therapies.
• Government agencies and defense organizations, particularly for therapies addressing conditions like acute radiation syndrome.
• Potential pharmaceutical or biotechnology partners for co-development, licensing, or commercialization of its product candidates.

FY2026 estForward Outlook

Wall Street analysts project Pluri Inc. revenue of about $2.6M for fiscal 2026, with EPS near $-2.70.

PLUR Valuation & Market Position

With a $21.49M market cap, Pluri Inc. sits in the micro-cap segment of the market. Relative to its peer group, PLUR's quantitative score of 64/100 is below the peer average of 76/100.

ROE 204%Key Financial Metrics

Return on equity for Pluri Inc. stands at 203.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.33 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -123.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Pluri Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -28.79 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Pluri Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Haifa, IL. The company is led by CEO Yaacov Yanay. PLUR has traded publicly since 2003.

PLUR Financials

PLUR Latest News

PLUR Analyst Consensus

PLUR MoonshotScore

What Investors Ask About Pluri Inc. (PLUR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources